Claims for Patent: 7,078,412
✉ Email this page to a colleague
Summary for Patent: 7,078,412
Title: | Quinuclidine derivatives and medicinal compositions containing the same |
Abstract: | The invention provides 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicy- clo[2.2.2] octane in salt form, pharmaceutical compositions comprising it, and methods of using it for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds. |
Inventor(s): | Fernandez Forner; Maria Dolors (Barcelona, ES), Prat Quinones; Maria (Barcelona, ES), Buil Albero; Maria Antonia (Barcelona, ES) |
Assignee: | Almirall Prodesfarma AG (Baar, CH) |
Application Number: | 11/116,777 |
Patent Claims: |
1. A compound which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicy- clo[2.2.2] octane wherein an anion X.sup.- is associated with the
positive charge of the nitrogen atom and wherein X.sup.- is a pharmaceutically acceptable anion of a mono- or polyvalent acid.
2. The compound according to claim 1 which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1- azoniabicyclo[2.2.2] octane bromide. 3. A pharmaceutical composition comprising a compound according to claim 1 in admixture with a pharmaceutically acceptable carrier or diluent. 4. The pharmaceutical composition of claim 3 comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3 -phenoxypropyl)-1-azoniabicyclo[2.2.2] octane bromide. 5. The pharmaceutical composition according to claim 3 further comprising a .beta..sub.2 agonist. 6. The pharmaceutical composition according to claim 4 further comprising a .beta..sub.2 agonist. 7. A method for treating chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis which method comprises administering to a human or animal patient in need of such treatment an effective amount of a compound according to claim 1. 8. The method according to claim 7 comprising administering to the patient an effective amount of 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicy- clo[2.2.2] octane bromide. 9. The method according to claim 7 further comprising administering to the patient an effective amount of a .beta..sub.2 agonists. 10. The method according to claim 8 further comprising administering to the patient an effective amount of a .beta..sub.2 agonist. |